• Advertise
  • About us
  • Terms and Conditions
  • Contact us
Friday, June 13, 2025
Australian Times News
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

New Covid treatment arrives in Australia ahead of official approval

The Government has imported an initial consignment of the drug Sotrovimab. But, as yet, there is no approval for its use in this country.

Mike Simpson by Mike Simpson
10-08-2021 03:00
in News
Image by Pete Linforth from Pixabay

Image by Pete Linforth from Pixabay

A new antibody treatment for Covid sufferers that is being brought into Australia by the Federal Government ahead of official approval should not be administered as there is not yet enough evidence to support its use.

The National Covid-19 Clinical Evidence Taskforce is recommending that the drug, Sotrovimab, not be used outside of clinical trials at this stage.

Taskforce director, Professor Julian Elliott, said there was not enough high-quality evidence to prove the drug worked.

“Based on the fact it was an interim analysis of a single study, with relatively low numbers, the panel decided to give an only-in-research recommendation, pending the availability of more data,” he said. “We don’t base our recommendations on press releases.”

The drug is already in use in several countries

But Professor Elliot added that he believed it was “reasonable” for the Government to bring in a small quantity of the drug and try to get ahead of the curve.

Sotrovimab has already been purchased by several countries, but Australian protocols require that it approved for use here by the Therapeutic Goods Administration.

Sotrovimab is an antibody treatment often given to high-risk patients as soon as they become ill with Covid. Various overseas trials have indicated that it provides additional protection to those who are, for example, obese or elderly.

AlsoRead...

Leading with Trust: Why Quality still wins in the AI Era

Leading with Trust: Why Quality still wins in the AI Era

5 June 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

28 May 2025

Over the weekend, Federal health minister Greg Hunt said the Australian Government had secured an initial shipment of over 7,700 doses.

He added the treatment had been shown to dramatically reduce hospitalisation and risk of death in adults with mild to moderate Covid-19, who are at risk of developing more severe Covid symptoms.

One of the main ways the body defends itself

The minister did stress approval from the Therapeutic Goods Administration would be required prior to medical practitioners being able to give it to patients.

According to the Federal Government, antibodies are proteins produced by our own body’s immune system and are one of the main ways the body defends itself against diseases.

Antibodies work by binding to a specific target – for example, a virus or a bacteria – and making them harmless. They block or slow down the action of the virus or bacteria, or they flag it as ‘foreign’ so that other parts of our immune system can clear the ‘invaders’ away.

Monoclonal antibodies work in the same way. They are laboratory-made proteins that mimic our body’s immune system to help fight off harmful pathogens and can be used to help treat people who already have Covid.

Tags: Covid-19 in AustraliahealthMedical sciencemedicine
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss

Leading with Trust: Why Quality still wins in the AI Era

by Pauline Torongo
5 June 2025
Leading with Trust: Why Quality still wins in the AI Era
Business & Finance

If you're leading a software team today, you've likely noticed the shift: faster feature rollouts, routine automation, and AI taking...

Read more

How to Save on Airport Parking: Budget Tips Every Traveller Should Know

by Fazila Olla-Logday
3 June 2025
How to Save on Airport Parking
Travel

Saving money on airport parking can be a challenge,but here are some budget friendly tips to help you navigate.

Read more

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

by Pauline Torongo
28 May 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin
Business & Finance

Bélanger-Martin’s ambitions stretch beyond redefining inflight comfort—they’re rooted in resurrecting the romance of supersonic travel with a modern twist.

Read more

Why a Gluten Free Hamper is simply the Best Gift for a Coeliac

by Fazila Olla-Logday
22 May 2025
Gluten Free Hamper
at

Buying a thoughtful gift can be tricky at the best of times, but when someone has dietary restrictions like coeliac...

Read more

Biela.dev is quietly becoming the Infrastructure Layer for the Next Internet

by Pauline Torongo
15 May 2025
Biela.dev is quietly becoming the Infrastructure Layer for the Next Internet
Technology

Biela.dev is not merely a consumer app; it is infrastructure. It could be a layer that powers the next generation...

Read more

The Battle for the Premier League’s Fifth Champions League Spot: Who Will Prevail?

by Fazila Olla-Logday
8 May 2025
Premier-Leagues-Fifth-Champions-League-Janosch-Diggelmann-Unsplash
at

As the Premier League season nears its climax, the race for the coveted Champions League places is tighter and more...

Read more

The Predictive Infrastructure: How BOF’s Neuro Finance System Reengineers Market Forecasting

by Pauline Torongo
5 May 2025
The Predictive Infrastructure: How BOF’s Neuro Finance System Reengineers Market Forecasting
Business & Finance

As global markets become more complex and volatile, BOF Investments has developed Neuro Finance, a predictive system that combines machine...

Read more
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status